<DOC>
	<DOCNO>NCT01337401</DOCNO>
	<brief_summary>The study two-arm , randomise , double-blind , international , multi-centre phase II trial cediranib Alveolar Soft Part Sarcoma ( ASPS ) . The study aim confirm ability cediranib halt disease progression patient metastatic ASPS , measure change tumour size 24 week randomisation , produce objective response accord RECIST criterion .</brief_summary>
	<brief_title>A Trial Cediranib Treatment Patients With Alveolar Soft Part Sarcoma ( CASPS )</brief_title>
	<detailed_description>Patients age 16 year old histologically confirm diagnosis ASPS recruit . Eligible patient randomise receive cediranib ( 30 mg daily po ) placebo ( 30 mg daily po ) 2:1 ratio . At 24 week post randomisation , treatment unblinded time patient placebo progressed active treatment give cediranib . Treatment continue objective disease progression death .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Alveolar Soft Part</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<criteria>1 . Histologically confirm diagnosis ASPS ( central confirmation require study entry ) 2 . Age 16 year old 3 . Availability archive tissue block unstained slide enable confirmation ( X ; 17 ) translocation 4 . ECOG Performance Status 01 5 . Life expectancy &gt; 12 week 6 . Progressive disease define RECIST v1.1 within 6 month prior randomisation 7 . Measurable metastatic disease use RECISTv1.1 , i.e . least one lesion 10 mm diameter ( 15 mm short axis nodal lesion ) assessable CT ( MRI brain metastasis ) . 8 . Patients brain metastasis permit provided disease control stable dose corticosteroid and/or nonenzyme induce anticonvulsant 9 . The capacity understand patient information sheet ability provide write informed consent 10 . Willingness ability comply schedule visit , treatment plan , laboratory test study procedure 11 . Able swallow retain oral medication 1 . Inadequate bone marrow reserve demonstrate absolute neutrophil count ≤1.5 x 109/L platelet count ≤100 x 109/L 2 . Serum bilirubin ≥ 1.5 x ULN ( unless Gilbert 's syndrome ) 3 . ALT AST ≥ 2.5 x ULN . If liver metastasis present , ALT AST &gt; 5 x ULN 4 . Serum creatinine &gt; 1.5 x ULN creatinine clearance ( calculate measure ) ≤ 50mL/min 5 . Greater +1 proteinuria unless urinary protein &lt; 1.5g 24 hr period protein/creatinine ratio &lt; 1.5 . 6 . History significant gastrointestinal impairment , judge Investigator , would significantly affect absorption cediranib . 7 . Patients history poorly control hypertension rest blood pressure &gt; 150/100 mmHg presence absence stable regimen antihypertensive therapy . 8 . Any evidence severe uncontrolled comorbidities e.g . unstable uncompensated respiratory , cardiac , hepatic renal disease , active uncontrolled infection . 9 . Evidence prolong QTc &gt; 480 msec ( use Bazetts correction , formula : QTc = QT/√RR ) history familial long QT syndrome . 10 . Significant recent haemorrhage ( &gt; 30mL bleeding/episode previous 3 month ) haemoptysis ( &gt; 5mL fresh blood previous 4 week ) . 11 . Major thoracic abdominal surgery 14 day prior entry study , surgical incision fully heal . 12 . Pregnant breastfeeding woman ; woman childbearing potential positive pregnancy test prior receive study medication ; woman intention pregnancy study treatment ; woman child bear potential unwilling urine serum pregnancy test prior study entry ( even surgically sterilise ) . 13 . Men woman childbearing potential unwilling use adequate birth control measure ( e.g . abstinence , oral contraceptive , intrauterine device , barrier method spermicide , implantable injectable contraceptive surgical sterilisation ) duration study continue precaution 2 week receive last study treatment . 14 . History anticancer ( include investigational , nonregistered ) treatment four week prior first dose cediranib , exception palliative radiotherapy symptom control . 15 . Previous treatment cediranib . 16 . Known hypersensitivity excipient cediranib . 17 . History malignancy ( except adequately treat basal squamous cell carcinoma carcinoma situ ) within 5 year , unless patient disease free 2 year tissue diagnosis primary cancer interest target lesion . 18 . Other concomitant anticancer therapy ( include LHRH agonist ) except steroid 19 . Recent history thrombosis 20 . Patients brain metastasis symptomatic require increase steroid previous six week study entry evidence recent and/or active bleeding , cause uncontrolled seizure .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cediranib</keyword>
	<keyword>ASPS</keyword>
	<keyword>Sarcoma</keyword>
</DOC>